The results of in vitro and in vivo clinical studies clearly indicated that not all FGFR1-amplified LSQCCs are sensitive to FGFR inhibitors and this observation suggests that some mechanisms of primary resistance are frequent in FGFR1-amplified lung cancer [52]. This evidence concerns the gene FGFR1 and lung cancer.